Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 5/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197240 | 0.91 | POLB (0.45) | CA2CAMK2ALMNA | |
| SCHEMBL108145 | 0.85 | CA2 (0.54) | CA2CAMK2AFNTAFNTBTAAR1 | |
| SCHEMBL13203128 | 0.83 | POLB (0.58) | CA2CAMK2A | |
| SCHEMBL10137771 | 0.83 | HPGD (0.55) | CTBP2LMNANPC1RAB9A | |
| SCHEMBL10137814 | 0.83 | CA2 (0.56) | CA2CAMK2ALMNA | |
| SCHEMBL16379390 | 0.83 | ALDH1A1 (0.48) | LMNANPC1RAB9A | |
| SCHEMBL15160745 | 0.83 | POLB (0.40) | CA2CAMK2A | |
| SCHEMBL449728 | 0.82 | CA2 (0.50) | CA2CAMK2AFNTAFNTBTAAR1 | |
| SCHEMBL21341936 | 0.81 | PTGS1 (0.53) | ESR1LMNA | |
| SCHEMBL7823277 | 0.81 | NPC1 (0.50) | SLC6A2CTBP2LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| EP-2809660-B1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014066726-A2 | COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013116682-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| US-5512059-A | DYEING POLYUREHTANE ELASTIC FIBERS INCLUDING CHLORINE-INDUCED DEGRADATION INHIBITORS THAT DO NO ELUTE OUT | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1996-04-30 | — | — | US | disclosed |
| US-5456960-A | A multicomponent yarn comprising a polyurethane elastic fiber containing one or more chlorination resistant inhibitors selected from the group consisting of oxides and hydroxides of magnesium, zinc, aluminum and hydrotalcite | TOYO BOSEKI KABUSHIHI KAISHA (JP) | 1995-10-10 | — | — | US | disclosed |
| EP-0489395-B1 | Dyed mixed knit fabric and method for its manufacture | TOYO BOSEKI (JP) | 1995-09-27 | — | — | EP | disclosed |
| EP-0426804-B1 | 2-(2-HYDROXY-3-PHENOXYPROPYLAMINO)-ETHOXYBENZENE DERIVATIVES | ICI PLC (GB) | 1994-01-19 | — | — | EP | disclosed |
| EP-0489395-A1 | Dyed mixed knit fabric and method for its manufacture | Toyo Boseki Kabushiki Kaisha (JP) | 1992-06-10 | — | — | EP | disclosed |
| EP-0426804-A1 | 2-(2-HYDROXY-3-PHENOXYPROPYLAMINO)-ETHOXYBENZENE DERIVATIVES. | ICI PLC (GB) | 1991-05-15 | — | — | EP | disclosed |
| WO-1990013535-A1 | COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA2 3454/4885CAMK2A 2142/4885FNTA 410/4885 |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | CA2 749/4885CAMK2A 1410/4885FNTA 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.